PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Novikoff, A. ; Müller, T.D.

Antagonizing GIPR adds fire to the GLP-1R flame.

Trends Endocrinol. Metab. 35, 566-568 (2024)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Unimolecular co-agonists at the GLP-1/GIP receptors have recently achieved remarkable anti-obesogenic feats; yet, in a recent Phase 1 clinical trial, Véniant and colleagues report astounding body-weight loss, and an appreciable safety profile, in participants with obesity using the GLP-1R agonist/GIPR antagonist AMG 133.
Impact Factor
Scopus SNIP
Altmetric
11.400
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Language english
Publication Year 2024
HGF-reported in Year 2024
ISSN (print) / ISBN 1043-2760
e-ISSN 1879-3061
Journal Trends in Endocrinology and Metabolism
Quellenangaben Volume: 35, Issue: 7, Pages: 566-568 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
POF-Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-501900-221
G-502200-001
DOI 10.1016/j.tem.2024.04.016
WOS ID 001267772200001
Scopus ID 85193281483
PubMed ID 38763780
Erfassungsdatum 2024-07-18
[➜Report correction]